 |
Doug Macron is the editor of GenomeWeb's Gene Silencing News. He covers research and therapeutic applications of RNAi, miRNA, and other gene-silencing technologies. E-mail Doug Macron or follow his GenomeWeb Twitter account at @Genesilencing. |
Mirna Reports Preclinical Data on Lead miRNA Replacement Drug, Focusing on Upcoming Phase I
January 24, 2013
Mirna Reports Preclinical Data on Lead miRNA Replacement Drug, Focusing on Upcoming Phase I
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Mirna Becomes First to Advance Therapeutic microRNA Mimic into Human Testing
May 2, 2013 / Gene Silencing News - NIH Awards $1.2M in Grants to Four Companies Developing RNAi, miRNA Cancer Drugs
October 4, 2012 / Gene Silencing News - Mirna Reports on Role of miR-34a in B Cell Lymphoma, Expands Planned Phase I Beyond Liver Cancer
May 3, 2012 / Gene Silencing News - Marina Preps for Additional Patient Enrollment in FAP Trial, Predicts Pharma Partnership This Year
January 26, 2012 / Gene Silencing News - Mirna Inks Deal to Use Marina's Smarticle Delivery Technology with miRNA Mimics
January 5, 2012 / Gene Silencing News